Another Bispecific, humanized IgG1 antibody that's beneath investigation is zenocutuzumab (MCLA-128), which functions by means of two impartial mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells by using ADCC. MCLA-128 capabilities by means of a ‘dock and block’ system whereby 1 arm of your antibody binds https://www.directivepublications.org/journal-of-clinical-breast-cancer/